Making cancer care smarter with Oncotype DX tests



Physician Login

Healthcare Professionals

Patients & Caregivers

About Oncotype IQ

 Contact Us

In collaboration with thousands of physicians around the world, over one million patients improved their outcomes with the Oncotype IQ portfolio of genomic tests.

See What's New

The only genomic test proven to predict a patient’s individual benefit from chemotherapy.

For patients with early-stage, ER-positive, HER2-negative, node negative, and node-positive (1-3) breast cancer, the Oncotype DX Breast Recurrence Score quantifies the risk of distant recurrence and the likelihood of chemotherapy benefit.

About the Test

READ MORE
The only genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma in situ.

For patients with ductal carcinoma in situ (DCIS) treated by local excision, with or without tamoxifen, the Oncotype DX Breast DCIS Score can help guide personalized treatment decisions.

About the Test

READ MORE
Decide whether immediate treatment is necessary or confidently opt for active surveillance.

For patients with clinically low-risk prostate cancer (very low, low, or intermediate NCCN risk) the Oncotype DX Genomic Prostate Score predicts the likelihood of favorable pathology (low-grade [3+3, 3+4], organ-confined disease).

About the Test

READ MORE
The first and only test to identify patients who will not respond to AR-targeted therapies

For patients with metastatic castration resistant prostate cancer, the Oncotype DX AR-V7 Nucleus Detect test identifies patients resistant to androgen receptor (AR) therapies such as abiraterone and enzalutamide.

About the Test

READ MORE
A genomic test that quantifies the risk of recurrence, for insight beyond traditional measures.

For patients with stage II or II A/B colon cancer whose tumor has been resected, the Oncotype DX Colon Recurrence score can help guide decisions about adjuvant treatment.

About the Test

READ MORE

The only genomic test proven to predict a patient’s individual benefit from chemotherapy.

For patients with early-stage, ER-positive, HER2-negative, node negative, and node-positive (1-3) breast cancer, the Oncotype DX Breast Recurrence Score quantifies the risk of distant recurrence and the likelihood of chemotherapy benefit.

About the Test
The only genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma in situ.

For patients with ductal carcinoma in situ (DCIS) treated by local excision, with or without tamoxifen, the Oncotype DX Breast DCIS Score can help guide personalized treatment decisions.

About the Test
Decide whether immediate treatment is necessary or confidently opt for active surveillance.

For patients with clinically low-risk prostate cancer (very low, low, or intermediate NCCN risk) the Oncotype DX Genomic Prostate Score predicts the likelihood of favorable pathology (low-grade [3+3, 3+4], organ-confined disease).

About the Test
The first and only test to identify patients who will not respond to AR-targeted therapies

For patients with metastatic castration resistant prostate cancer, the Oncotype DX AR-V7 Nucleus Detect test identifies patients resistant to androgen receptor (AR) therapies such as abiraterone and enzalutamide.

About the Test
A genomic test that quantifies the risk of recurrence, for insight beyond traditional measures.

For patients with stage II or II A/B colon cancer whose tumor has been resected, the Oncotype DX Colon Recurrence score can help guide decisions about adjuvant treatment.

About the Test

Oncotype DX AR-V7 Nucleus Detect test now covered by Medicare for your mCRPC patients

In mCRPC, know when it's time to shift away from AR-targeted therapy. Direct your mCRPC patients toward the right course of treatment.

Learn About the Test



Real People.
Real Results.

When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.

Learn More



Healthcare Savings

How much do ineffective cancer treatments cost the healthcare system? In the US alone, Oncotype IQ tests have saved more than $3.5 billion.

Learn More



Practice Tools

The Eighth Edition AJCC Staging Manual is now effect, and it has changed staging for T1-2 N0 M0 breast cancer patients.

Learn How



Latest TAILORx Data

The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.

Learn More

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.



Home

Licenses

14-day-billing-policy

Terms & Conditions

Worldwide Websites

In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Breast Recurrence Score, Recurrence Score, DCIS score, Colon Recurrence Score Genomic Prostate Score, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are registered trademarks of Genomic Health, Inc.

Making cancer care smarter.™



We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

Available Now

Prospective Outcomes:
TAILORx

Genomics Infographic

Clinical Utility:
Active Surveillance

Clinical Comparator Trial

Do You Really Need Radiation Therapy?

Do You Really Need Chemotherapy?

Real Patients. Real Stories.

News Coverage

Get Our Patient Brochure

Oncotype DX AR-V7 Nucleus Detect test now covered by Medicare for your mCRPC patients

Stay in Touch

Healthcare Professionals

Patients & Caregivers

Resources

Oncotype DX AR-V7 Nucleus Detect test now covered by Medicare for your mCRPC patients

Sign up for Our Healthcare Professional Updates

Stay in Touch

Healthcare Professionals

Patients & Caregivers

Resources